Richard Ding

This profile gathers the share dealings of Richard Ding in Moberg Pharma AB (publ), where the filings describe the role as board member. Over a trading history stretching from 23 June 2025 to 21 August 2026, the count stands at 9 filings.

In open-market terms, that means 6 purchases worth €7,931 on one side and 3 sales worth €776k on the other. Netting one side against the other leaves €768k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and 3 sales.

Half of the purchases are above €894 and half below. As a share of market capitalisation, the median purchase stands at 0.0021%, based on 5 purchases. Clusters matter here: 2 out of 5 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 21 August 2026 with an open-market purchase (€966) in Moberg Pharma AB (publ). The median gap between a trade and its publication by Finansinspektionen is 3 days. The legal deadline for notifying a trade is three business days (MAR article 19). These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.